Physiological and pharmacokinetic effects of multilevel caging on Sprague Dawley rats under ketamine-xylazine anesthesia.
While the cage refinement is a necessary step towards improving the welfare of research rats, increasing the complexity and surface area of the living space of an animal may have physiological impacts that need to be taken into consideration. In this study, ketamine (80 mg/kg) and xylazine (10 mg/kg) caused a short duration anesthesia that was significantly decreased in Sprague-Dawley rats housed in multilevel cages (MLC), compared to rats housed in standard cages (SDC). The withdrawal reflex, the palpebral reflexes and the time-to-sternal all occurred earlier in MLC housed rats, suggesting an effect of housing on the physiology of the rats. In addition, during anesthesia, cardiac frequencies were increased in animals housed in the smaller SDC. Respiratory frequencies, the blood oxygen saturation and rectal temperatures during anesthesia did not vary between conditions during the anesthesia. While xylazine pharmacokinetics were unchanged with caging conditions, the clearance and half-lives of ketamine and its metabolite, norketamine, were altered in the rats housed in MLC. Finally, while no difference was ultimately seen in rat body weights, isolated liver and adrenal gland weights were significantly lighter in rats housed in the MLC. Increasing cage sizes, while having a positive impact on wellbeing in rats, can alter anesthetic drug metabolism and thus modify anesthesia parameters and associated physiological processes.
Department of Veterinary Biomedicine, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada.
Aurore
A
Dodelet-Devillers
Chiara
C
Zullian
Francis
F
Beaudry
Jim
J
Gourdon
Julie
J
Chevrette
Pierre
P
Hélie
Pascal
P
Vachon
D000778:Anesthetics, Dissociative / Q000493:pharmacokinetics* / Q000494:pharmacology; D000818:Animals; D006207:Half-Life; D006799:Housing, Animal; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics* / Q000494:pharmacology; D007649:Ketamine / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000494:pharmacology; D008297:Male; D051381:Rats / Q000502:physiology*; D017207:Rats, Sprague-Dawley; D012018:Reflex / Q000187:drug effects; D013047:Specific Pathogen-Free Organisms; D014991:Xylazine / Q000493:pharmacokinetics* / Q000494:pharmacology
D000778:Anesthetics, Dissociative; D006993:Hypnotics and Sedatives; D014991:Xylazine; D007649:Ketamine; C033419:norketamine